Recently, the OlympiA phase 3 trial showed that patients with high-risk, HER2-negative early breast cancer who have germline BRCA1 or BRCA2 pathogenic or likely pathogenic alterations benefited from adjuvant olaparib [27]. This evidence concerns the gene ERBB2 and breast carcinoma.